|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1-antitrypsin D256V and L41P variants
Department of Molecular Biology, Sejong University, Kwangjin-gu, Seoul 143-747, Korea
(RECEIVED August 7, 2003; FINAL REVISION November 28, 2003; ACCEPTED November 29, 2003)
1-Antitrypsin is the most abundant protease inhibitor in plasma and is the archetype of the serine protease inhibitor superfamily. Genetic variants of human
1-antitrypsin are associated with early-onset emphysema and liver cirrhosis. However, the detailed molecular mechanism for the pathogenicity of most variant
1-antitrypsin molecules is not known. Here we examined the structural basis of a dozen deficient
1-antitrypsin variants. Unlike most
1-antitrypsin variants, which were unstable, D256V and L41P variants exhibited extremely retarded protein folding as compared with the wild-type molecule. Once folded, however, the stability and inhibitory activity of these variant proteins were comparable to those of the wild-type molecule. Retarded protein folding may promote protein aggregation by allowing the accumulation of aggregation-prone folding intermediates. Repeated observations of retarded protein folding indicate that it is an important mechanism causing
1-antitrypsin deficiency by variant molecules, which have to fold into the metastable native form to be functional.
Keywords:
1-antitrypsin; conformational disease; folding; metastability; serpin
Reprint requests to: Hana Im, Department of Molecular Biology, Sejong University, 98 Gunja-dong, Kwangjin-gu, Seoul 143-747, Korea; e-mail: hanaim{at}sejong.ac.kr; fax: 82-2-3408-3661.
Article published online ahead of print. Article and publication date are at http://www.proteinscience.org/cgi/doi/10.1110/ps.03356604.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
P K Lovelock, S Healey, W Au, E Y M Sum, A Tesoriero, E M Wong, S Hinson, R Brinkworth, A Bekessy, O Diez, et al. Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants J. Med. Genet., January 1, 2006; 43(1): 74 - 83. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |